Bortezomib Completed Phase 2 Trials for Myelodysplastic Syndrome / Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01323920Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors